Compare Alliant Energy Corporation (LNT) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alliant Energy Corporation vs Novartis AG — how do they compare? Alliant Energy Corporation trades at $65.85 (market cap $16.99B), while Novartis AG trades at $143.75 (market cap $268.57B). The key difference: Novartis AG is far larger — about 15.8× Alliant Energy Corporation's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Alliant Energy Corporation for 64 Days and Novartis AG for 82 Days on average.
| LNT | NVS | |
|---|---|---|
Market Cap | $16.99B | $268.57B |
Volume | 2,488,387 | 1,532,573 |
Sector | Utilities | Health |
52-Week High | $78.03 | $168.62 |
52-Week Low | $63.21 | $121.80 |
Typical Hold Time | 64 Days | 82 Days |
Enterprise Value | $29.08B | $309.89B |
Dividend Yield | 3.27% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LNT trades at $65.85, up 0.98% today, with a bullish technical signal and strong earnings beats in recent quarters. The company reported 2025 revenue of $4.36B and net income of $810M, with a net margin of 18.56%. A $13.4B capital investment plan supports long-term growth, while analyst consensus is a Buy with a $77.00 price target, implying significant upside from current levels.
Outlook remains positive due to steady utility demand and data center growth, but risks include rising debt levels and cost pressures. The stock offers a defensive profile with a 23-year dividend growth history, though valuation multiples like a P/E of 20.74 require sustained earnings expansion to justify further gains.
Novartis (NVS) trades at $143.75, up 0.33% on the day, near the consensus price target of $146.00. Recent earnings show mixed quarterly beats and a miss in Q1 2026, with revenue growth to $56.67B in 2025 and a net income margin of 24.67%. Technical indicators signal a bearish trend, while analyst sentiment is mixed with 24% buy ratings. The company recently announced a $7.8B licensing deal with China's Abogen for mRNA therapy, but faces scrutiny over clinical setbacks and M&A strategy.
The outlook for NVS hinges on execution of its pipeline and deal integration amid investor caution. Opportunities include expansion into autoimmune treatments and solid profitability, but risks involve trial failures, regulatory probes, and debt levels rising to 30.26% of assets. Wall Street remains neutral with a slight upside to the price target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
